臨床検査52巻13号

2008年12月発行

今月の主題 凝固制御 抗凝固薬の新展開

抗Xa薬

著者： 小嶋哲人¹

所属機関： ¹名古屋大学医学部保健学科検査技術科学専攻

ページ範囲：P.1575 - P.1579

　Xaを標的にした抗凝固薬には，アンチトロンビンを介する間接抗Xa薬と直接抑制する直接抗Xa薬がある．間接抗Xa薬には，合成ヘパリン類似分子であるペンタサッカライド(フォンダパリヌクス)があり，日本においても下肢整形外科手術の静脈血栓塞栓症発症予防薬として優れた臨床効果を発揮している．また，メチル化ペンタサッカライド(イドラパリヌクス)や経口薬も含め現在数多くの抗Xa薬が臨床開発中である．

参考文献

1) 小嶋哲人：抗凝固薬の歴史とXa阻害薬の開発目的を探る．Xa阻害薬のすべて(池田康夫，坂田洋一，丸山征郎編)，先端医学社，pp68-75, 2007

2) McLean J：The thromboplastic action of cephalin. Am J Physiol　41：250-257, 1916

3) Alban S：From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest　35：12-20, 2005

4) Oosta GM, Gardner WT, Beeler DL, et al：Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA　78：829-833, 1981

5) Choay J, Petitou M, Lormeau JC, et al：Structure-activity relationship in heparin：a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun　116：492-499, 1983

6) Eriksson BI, Bauer KA, Lassen MR, et al：Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med　345：1298-1304, 2001

7) Bauer KA, Eriksson BI, Lassen MR, et al：Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med　345：1305-1310, 2001

8) Lassen MR, Bauer KA, Eriksson BI, et al：Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery：a randomised double-blind comparison. Lancet　359：1715-1720, 2002

9) Turpie AG, Bauer KA, Eriksson BI, et al：Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery：a randomised double-blind trial. Lancet　359：1721-1726, 2002

10) Turpie AG, Bauer KA, Eriksson BI, et al：Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery：a meta-analysis of 4 randomized double-blind studies. Arch Intern Med　162：1833-1840, 2002

11) Bauer KA, Hawkins DW, Peters PC, et al：Fondaparinux, a synthetic pentasaccharide：the first in a new class of antithrombotic agents-the selective factor Xa inhibitors. Cardiovasc Drug Rev　20：37-52, 2002

12) Lormeau JC, Herault JP：The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost　74：1474-1477, 1995

13) Alban S, Greinacher A：Role of sulfated polysaccharides in the pathogenesis of HIT. In：Heparin-Induced Thrombocytopenia, 2nd Edition(Warkentin TE, Greinacher A eds), Marcel Dekker, New York, pp167-187, 2001

14) Amiral J, Lormeau JC, Marfaing-Koka A, et al：Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis　8：114-117, 1997

15) Gross PL, Weitz JI：New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol　28：380-386, 2008

16) Gerotziafas GT, Samama MM：Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des　11：3855-3876, 2005

17) Hara T, Yokoyama A, Ishihara H, et al：DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost　71：314-319, 1994

18) Hérault JP, Bernat A, Pflieger AM, et al：Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther　283：16-22, 1997

flow chamber. Thromb Haemost　98：883-888, 2007